Digitizing Healthcare – Embracing change. Creating opportunity.

Emily Wyatt

The future of healthcare is digital

For many industries, embracing digitization has become a matter of survival. Healthcare has always had a reputation of being resistant to change, but consumer demand and a rapidly evolving technology-driven world have led the digitization of healthcare to move at a frantic pace.

In comparison with other industries, healthcare has been slow to take advantage of the digital revolution. Traditionally healthcare has always been a difficult industry in which to innovate; it is highly regulated, expensive, complex and risk averse. However, rising drug development costs, increased patient expectations, and a growing dependence on health resources, place the industry under increasing pressure to move with the times. Many organizations with an interest in health, including the pharmaceutical industry, medical technology companies, health insurers, and payers are focusing on the digital world. However, the strongest digital health innovators are now coming in from outside the industry.

How tech companies are driving digital transformation

Healthcare represents an incredibly lucrative opportunity for traditional technology companies. The tech giants – Alphabet (the parent company of Google), Amazon, Apple, Microsoft and IBM – are taking the lead and heavily investing their time, resource and talent into healthcare.

Each of the major tech companies are using their core business strengths to create digital health initiatives across a variety of platforms. These are being implemented at every touchpoint of the patient/health professional journey ranging from data storage, artificial intelligence (AI), e-commerce, voice-enabled solutions, consumer apps and wearables. By developing tools that patients and health professionals embrace, and through collaborations with healthcare providers, the Big 5 are poised to reinvent the healthcare industry.

Digitizing Healthcare White Paper from Deallus
DOWNLOAD WHITEPAPER

About the author

Emily Wyatt

Emily is a Senior Associate based in the London office. Since joining Deallus, Emily has lead research for top tier pharmaceutical clients supporting their global strategy to implement personalised healthcare initiatives across the value chain. She has also facilitated competitive simulation workshops looking at the impact of Tech disruption in healthcare. Emily has significant experience across a variety of therapeutic areas and industries including neuroscience, oncology, immune-oncology, companion diagnostics, liver diseases, autoimmune diseases and personalised healthcare.

Emily holds a MPhil in Bioscience Enterprise from the University of Cambridge and a BSc Honours in Biochemistry from the University of Bristol. Throughout her career, Emily has also developed strong expertise in the medical devices space, having led business development projects for medical device companies in oncology and inflammatory diseases.

You may also be interested in…

  • AI in pharma

Can AI really help you understand what matters in your market?

The impact of AI across our industry will be profound. It’s already driving faster identification of novel drug targets and drug discovery, better patient identification, accelerated drug development, earlier diagnosis, and more personalized healthcare.

  • Brain Awareness Week

Brain Awareness Week

Brain Awareness Week is a global campaign held every March that aims to increase public support and excitement for brain science.

  • Rare Disease Day

Rare Diseases, Pharma’s Perennial Hitmaker

February 29th is the rarest day of the year, and this was in fact the reason why Rare Disease Day was established on this day 16 years ago by the European Organisation for Rare Diseases, commemorating the 25th anniversary of the U.S. Orphan Drug Act.

  • National Healthcare Security Administration (NHSA) protocols

National Healthcare Security Administration (NHSA) protocols

On 4 July 2023, the National Healthcare Security Administration (NHSA) published the drafted 'Protocol for Renewal of NRDL Listed Drugs’ and ‘Negotiation Rules for Non-Exclusive Drug’. The two protocols aim to streamline the negotiation process for NRDL listed drugs and those with generic versions and are eligible for NRDL listing.

To learn more about this topic, or to find out about ways in which Deallus can help you, please get in touch.

For any questions or comments on this thought piece, please reach out to Julie Munch Khan – Deallus Chief Commercial Officer

Julie Munch Khan – Deallus Chief Commercial Officer